Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MTTP | P55157 | 11/20 | 0.44 |
| ▸ | APOB | P04114 | 4/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793812 | 0.90 | CHRNB2 (0.48) | SMOCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6788028 | 0.86 | FPR2 (0.54) | CTSSCTSKMTTPAPOBPTPN1 | |
| SCHEMBL6788025 | 0.86 | FPR2 (0.54) | CTSSCTSKMTTPAPOBPTPN1 | |
| SCHEMBL6794333 | 0.85 | MTTP (0.51) | CTSSCTSKMTTPAPOB | |
| SCHEMBL6794335 | 0.85 | MTTP (0.51) | CTSSCTSKMTTPAPOB | |
| SCHEMBL6793585 | 0.83 | SMO (0.49) | SMOCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL29666452 | 0.80 | CTSS (0.57) | HDAC8CTSSCTSK | |
| SCHEMBL27744391 | 0.79 | CYP17A1 (0.55) | HDAC8CTSSCTSK | |
| SCHEMBL6892615 | 0.79 | CTSS (0.61) | HDAC8CTSSCTSKSCN9A | |
| SCHEMBL6795020 | 0.78 | CHRNB2 (0.52) | SMOCHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885HDAC8 2196/4885CHRNB2 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.